Our First Year in Review – Announcing the launch of our NEW website
This month marks the first anniversary of the launch of The Silverstein Foundation for Parkinson’s with GBA. We are humbled by the outpouring of support that we have received from far and wide. Friends, family, individuals impacted by Parkinson’s Disease (PD), and notably, the healthcare and biotechnology communities have rallied around Jonathan and the Foundation’s important work. Our many accomplishments to date include the distribution of eleven grants to academic institutions and private biotechnology companies in support of research in multiple modalities including enhancing autophagy, GCase activation, protein degradation and gene therapy. Most significantly, in collaboration with REGENXBIO and OrbiMed, we launched Prevail Therapeutics, a private company focused on developing novel biologic therapies for GBA-associated PD and other neurodegenerative diseases. On March 8th, Prevail announced a $75 million Series A financing. It is our hope that Prevail will be ready to test its first product in humans within a year. While we are off to an incredible start, we are only just beginning. THANK YOU for your continued support as we work to accelerate the pace of research to bring disease-modifying therapeutic options to PD patients.
- We have assembled an incredible Scientific Advisory Board comprised of influential thought-leaders in GBA-associated PD and drug discovery.
- We’ve hired several independent consultants who are working with our team to vet potential research programs and review responses to RFP’s.
- We partnered with Sandbox, a Chicago-based marketing and communications company to create a NEW website.
- We hosted a joint workshop with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) on March 8th, gathering nearly 40 world-renowned experts. We are also partnering with MJFF on a research funding project to be announced on March 19th.
- A grant was made to MJFF, directed to specific GBA-related research.
- A grant was made to the Parkinson’sInstitute & Clinical Center in San Francisco to allow Executive Dir., Dr. Carrolee Barlow and her team to complete a study of the clinical manifestations of genetic as compared to sporadic PD as related to neurons in the GI tract.
- Two grants were made to Columbia University which were directed specifically to GBArelated research and bioinformatics. Two grants were made to Alector, a Calfornia-based biotechnology company developing novel immuno-neurology therapies for PD and other neurodegenerative diseases.
- A grant was made to Dr. Dimitri Krainc, Chairman of Neurology at Northwestern University, who is a global thought leader in GBA-associated PD biology, and the scientific founder of Lysosomal Therapeutics, which is one of only two companies currently running a clinical trial for GBA-PD. Our grant is funding the development of next-generation molecules.
- A grant was made to resTORbio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. In January 2018, the company raised $98 million in its initial public offering on the NASDAQ (see photo below).
- A grant was made to the Crews Laboratory at Yale University. Led by world-renowned biochemist, Dr. Craig Crews, the Crews Lab is working on controlling intracellular protein levels by using small molecules with a focus on PD targets.
- A grant was made to Arvinas, a biotechnology company based in Connecticut whose technology focuses on degrading toxic intracellular targets found in PD.
- As mentioned above, a grant was made to Prevail Therapeuticsto develop novel gene therapies for PD and other neurodegenerative diseases.
- Immediately after our launch, Celgene Corporation made a transformative donation of $5 million. We are deeply grateful to Celgene for this foundational support.
- In our first year, over 150 individuals have generously donated nearly $1 million to support our work. These donations have come from friends, family and strangers, in amounts from $18 to $250,000. Every donation is appreciated, and brings us closer to the cure.
In the News
- Jonathan appeared on Squawk Box and On the Money with Becky Quick on CNBC last summer. Video of these appearances can be found on the In The News page of our website.
- Later this month, Jonathan will be named to the Forbes Midas List for the seventh time.
We would like to express our thanks to Greg Waitley and his team at Sandbox for creating our new website, and to Steffanie Levin for designing our logo.